

Aggressive Capital Allocation Led to Suppressed Return Ratios

Est. Vs. Actual for Q3FY23: Revenue – **BEAT**; EBITDA Margin – **BEAT**; PAT – **BEAT**

Changes in Estimates post Q3FY23

FY23E/FY24E: Revenue 11.3%/22.1%; EBITDA Margins 15%/16%; PAT -47%/-7.2%

Recommendation Rationale

- Reported revenue grew by 35.3% YoY and was majorly contributed by Biosimilars (+53.5% YoY) and generics (+18.1% YoY). Adj. PAT of Rs 251 Cr increased by 14.2% YoY after adjusting one-time costs of Rs 271 Cr which arose due to the Viatris deal.
- Existing and new products (bAdalimumab, bBevacizumab, bAspart) in Europe and Emerging Markets added growth in the last quarter.
- In generics, geographical expansions (Liraglutide and Immunosuppressan) and the launch of new products added to the healthy growth.

Sector Outlook: Neutral

Company Outlook & Guidance: The capital allocation on two fronts R&D & acquisition of Viatris has led to a dilution in the return ratios to below ~10% despite growth in the business.

Current Valuation: PE22x for FY25 earnings (Earlier Valuation: PE21x)

Current TP: Rs 260/share (Earlier TP: Rs 310/share)

Recommendation: **HOLD**

Financial Performance

The company's reported revenue grew by 35.3% YoY, which was majorly driven by the Biosimilars (+53.5% YoY) and generics (+18.1% YoY). The Biosimilars segment included Viatris' Sales in the last quarter. The company's gross margins decreased by 52bps YoY due to changes in the product mix and price erosion in the business while EBITDA margins fell by 55bps due to an increase in the R&D Costs. Adj. PAT stood at Rs 251 Cr, increasing by 14.2% YoY after adjusting for the one-time cost of Rs 271 Cr, which arose due to the Viatris deal.

Outlook: In the US market, Biocon's market share stood stagnant at ~10% in gPegfilgrastim, gTrastuzumab, and gGlargine due to stiff competition from peers. However, the company has launched existing and new products (bAdalimumab, bBevacizumab, and bAspart) in Europe and Emerging Markets, adding growth in the last quarter. Biocon has a healthy pipeline of biosimilars like bAdalimumab, bDenosumab and bUstekinumab.

In generics, geographical expansions (Liraglutide & Immunosuppressan) and the launch of new products added healthy growth which is expected to continue in the upcoming quarters. **However, the capital allocation on two fronts R&D & Acqstion of Viatris has diluted return ratios to below ~10% despite growth in the business.**

Valuation & Recommendation: We expect improvement in Return Ratios is the key to re-rate stock in future, therefore, we recommend "HOLD"

Key Financials (Consolidated)

(Rs Cr)	Q3FY23	QoQ (%)	YoY (%)	Axis Est.	Variance %
Net Sales	2,941	26.8%	35.3%	2,436	20.8%
EBITDA	644	36.9%	32.0%	521	23.6%
EBITDA Margin	21.9%	161	-394	21.4%	-
Net Profit	251	14.2%	150.7%	229	9.6%
EPS (Rs)	2.1	14.2%	150.7%	1.9	9.6%

Source: Company, Axis Research

(CMP as of 15 Feb 2023)	
CMP (Rs)	238
Upside /Downside (%)	9.0%
High/Low (Rs)	406/229
Market cap (Cr)	28,430
Avg. daily vol. (6m)Shrs.	12,00,000
No. of shares (Cr)	120

Shareholding (%)

	Jun-22	Sep-22	Dec-22
Promoter	60.6	60.6	60.6
FII	16.3	15.8	14.4
MFs / UTI	3.1	3.2	4.0
Others	20.0	20.4	21.0

Financial & Valuations

Y/E Mar (Rs Cr)	FY23E	FY24E	FY25E
Net Sales	10,770	13,857	15,777
EBITDA	2,197	3,049	3,629
Net Profit	529	1,243	1,565
EPS (Rs)	4.4	10.4	13.0
PER (x)	54.0	23.0	18.3
P/BV (x)	21.0	15.0	12.3
EV/EBITDA (x)	2.0	1.9	1.7
ROE (%)	3.7%	8.1%	9.3%

Change in Estimates (%)


Y/E Mar	FY23E	FY24E	FY25E
Sales	2,489	2,823	3,249
EBITDA	330	347	435
PAT	205	200	263

ESG disclosure Score**

Environmental	N.A.
Social Disclosure Score	N.A.
Governance Disclosure	N.A.
Total ESG Disclosure	N.A.

Source: Bloomberg, Scale: 0.1-100

**Note: This score measures the amount of ESG data a company reports publicly and does not measure the company's performance on any data point. All scores are based on 2020 disclosures

Relative performance


Source: Capitaline, Axis Securities

Ankush Mahajan

Research Analyst

Email: ankush.mahajan@axissecurities.in

Key Risks to our Estimates and TP

- USFDA inspection and issuing of WL/OAI or 483 observations may impact the revenue growth
- Entry of new players may increase pricing pressure in the injectable portfolio
- Delay in launching new Biosimilars in the market

Change in Estimates

	New			Old			% Change		
	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
Sales	10,770	13,857	15,777	9,680	11,347	15,000	11.3%	22.1%	5.2%
EBITDA	2,197	3,049	3,629	2,304	2,665	3,500	-4.6%	14.4%	3.7%
PAT	529	1,243	1,565	1000	1,363	1,550	-47.1%	-8.8%	0.9%

Source: Company, Axis Securities

Results Review

Particulars (Rs crore)	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	YoY (%)	QoQ (%)
Net Sales	2174.2	2408.8	2139.5	2319.7	2941.1	35.3%	26.8%
Growth (%)	17.5%	31.0%	21.5%	26.0%	35.3%		
Total Expenditure	1686	1816.9	1740.1	1849.2	2296.8	36.2%	24.2%
Raw Material Consumed	712.9	828.3	702.8	752.4	979.6		
Gross margins (%)	67.2%	65.6%	67.2%	67.6%	66.7%	-52	-87
Employee Expenses	495	470.3	512.6	540	558.8	12.9%	3.5%
% of sales	22.8%	19.5%	24.0%	23.3%	19.0%	-377	-428
Other Expenses	478.1	518.3	524.7	556.8	758.4	58.6%	36.2%
% of sales	22.0%	21.5%	24.5%	24.0%	25.8%	495	-52
EBITDA	488.2	591.9	399.4	470.5	644.3	32.0%	36.9%
EBITDAM (%)	22.5%	24.6%	18.7%	20.3%	21.9%	-394	161
Interest	14.7	10.5	19.9	30	120.3		
Depreciation	205.7	212.2	217.5	230.8	301.1	46.4%	30.5%
Other Income	48.3	67.3	77.9	64.5	78.6		
Associate P/L	-47.2	-53	-43	-28.3	-55.6		
Exceptional Items	0	-41	-43	-17	-271.4		
PBT	268.9	342.5	153.9	228.9	-25.5	-109.5%	-111.1%
Tax	49.3	58.6	29.5	147.3	-4.8		
Tax (%)	18.3%	17.1%	19.2%	64.4%	18.8%		
Reported PAT	219.6	283.9	124.4	81.6	-20.7	-109.4%	-125.4%
Adjusted PAT	219.6	324.9	167.4	98.6	250.7	14.2%	154.3%

Source: Company, Axis Securities

Revenue Breakup

Particulars (Rs crore)	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	YoY (%)	QoQ (%)
Generics	607.4	717.2	579.7	622.8	717.6	18.1%	15.2%
Biosimilars	981.4	982.3	976.6	997.4	1506.6	53.5%	51.1%
Research services	641.4	758.1	644.5	768.1	785.9	22.5%	2.3%

Source: Company, Axis Securities

Financials (consolidated)

Profit & Loss

(Rs Cr)

Particulars (Rs Cr.)	FY22	FY23E	FY24E	FY25E
Net sales	8,184	10,770	13,857	15,777
Other operating income	15.2%	31.6%	28.7%	13.9%
Net Revenue	6,214	8,573	10,809	12,148
	2,718	3,543	4,504	5,080
Cost of goods sold	66.8%	67.1%	67.5%	67.8%
Contribution (%)	1,880	2,380	3,049	3,471
Other operating costs	23.0%	22.1%	22.0%	22.0%
	1,615	2,649	3,256	3,597
EBITDA	19.7%	24.6%	23.5%	22.8%
Other income	1,970	2,197	3,049	3,629
	24.1%	20.4%	22.0%	23.0%
PBIDT	68	288	400	390
Depreciation	1,903	1,910	2,648	3,239
Interest & Fin Chg.	23.2%	17.7%	19.1%	20.5%
E/o income / (Expense)	814	963	1,135	1,298
Pre-tax profit	213	288	240	178
Tax provision	-207	-180	-150	-100
(-) Minority Interests	-111	-372	0	0
Associates	983	682	1,604	2,019
Adjusted PAT	21.5%	22.5%	22.5%	22.5%
Other Comprehensive Inc	212	154	361	454
Reported PAT	772	529	1,243	1,565

Source: Company, Axis Securities

Balance Sheet

(Rs Cr)

Y/E Mar, Rs. Cr	FY22	FY23E	FY24E	FY25E
Share Capital	600	600	600	600
Reserves & Surplus	8,870	13,739	14,802	16,186
Shareholders Fund	9,470	14,339	15,402	16,786
Total Debt	4,904	19,829	19,329	18,829
Long Term Provisions	3,098	3,770	4,850	5,522
Total Non Current Liabilities	7,096	18,412	18,992	19,164
Trade Payables	1,609	2,125	2,733	3,112
Other Current Liabilities	1,314	2,154	2,771	3,155
Capital Employed	20,394	42,216	45,086	47,405
Gross Block	10,239	12,039	13,839	15,639
Depreciation	4,563	5,526	6,661	7,959
Net Block	5,677	6,514	7,179	7,681
CWIP	3,420	2,420	1,420	420
Fixed Assets	10,420	30,432	30,097	29,599
Deferred Tax Asset(Net)	293	293	293	293
Other Non Current Assets	936	797	2,025	3,167
Current Investments	1,218	1,218	1,218	1,218
Inventories	2,298	2,951	3,796	4,322
Trade Receivables	2,058	2,656	3,417	3,890
Cash & Cash Equivalents	1,748	2,215	2,214	2,659
Other Current Assets	1,061	1,292	1,663	1,893
TOTAL ASSETS	20,394	42,216	45,086	47,404

Source: Company, Axis Securities

Cash Flow

(Rs Cr)

Y/E Mar, Rs. Cr	FY22A	FY23E	FY24E	FY25E
PBT	983	682	1,604	2,019
Add: depreciation	814	963	1,135	1,298
Add: Interest	68	288	400	390
Cash flow from operations	1,865	1,933	3,139	3,707
Change in working capital	1,709	-686	899	937
Taxes	212	154	361	454
Miscellaneous expenses	0	0	0	0
Net cash from operations	-56	2,465	1,879	2,315
Capital expenditure	-1,891	-20,975	-800	-800
Change in Investments	193	-0	-0	-0
Net cash from investing	-1,698	-20,975	-800	-800
Increase/Decrease in debt	1,348	14,925	-500	-500
Dividends	-60	-160	-180	-180
Proceedings from equity	0	0	0	0
Interest	-68	-288	-400	-390
Others	265	4,500	0	-0
Net cash from financing	1,486	18,977	-1,080	-1,070
Net Inc./ (Dec.) in Cash	-268	468	-1	445
Opening cash balance	2,015	1,748	2,215	2,214
Closing cash balance	1,748	2,215	2,214	2,659

Source: Company, Axis Securities

Ratio Analysis

(%)

Y/E March	FY22A	FY23E	FY24E	FY25E
Sales growth %	15.2	31.6	28.7	13.9
OPM (%)	24.1	20.4	22.0	23.0
Oper. profit growth %	19.2	11.5	38.8	19.0
COGS / Net sales %	33.2	32.9	32.5	32.2
Depreciation / G. block %	8.0	8.0	8.2	8.3
Effective interest rate %	21.5	22.5	22.5	22.5
Net sales / Gr block (x)	0.8	0.9	1.0	1.0
RoCE %	10.2	4.8	6.2	7.2
Debt / equity (x)	0.5	1.4	1.3	1.1
Effective tax rate %	21.5	22.5	22.5	22.5
RoE %	8.1	3.7	8.1	9.3
Payout ratio (Div/NP)	7.8	30.3	14.5	11.5
EPS (Rs.)	6.4	4.4	10.4	13.0
EPS Growth %	-9.9	-31.5	135.0	25.9
CEPS (Rs.)	18.0	19.2	12.0	10.0
DPS (Rs.)	0.5	1.3	1.5	1.5

Source: Company, Axis Securities

Biocon Price Chart and Recommendation History



Date	Reco	TP	Research
01-Jan-21	BUY	505	Top Picks
25-Jan-21	BUY	435	Result Update
30-Apr-21	BUY	430	Result Update
23-Jul-21	HOLD	400	Result Update
22-Oct-21	BUY	370	Result Update
05-Nov-21	BUY	390	AAA
21-Jan-22	BUY	425	Result Update
29-Apr-22	BUY	425	Result Update
29-Jul-22	HOLD	335	Result Update
15-Nov-22	HOLD	310	Result Update
16-Feb-23	HOLD	260	Result Update

Source: Axis Securities

About the analyst

Analyst: Ankush Mahajan

Contact Details: ankush.mahajan@axissecurites.in

Sector: Midcaps/ Pharma Sector

Analyst Bio: Ankush Mahajan is MBA (Finance) from SMVDU with over 12 years of research experience in the Midcaps/ Pharma Sector

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
3. ASL has no material adverse disciplinary history as on the date of publication of this report.
4. I/We, Ankush Mahajan, MBA - (Finance), author/s and the name/s subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, etc. in the subject company in the last 12-month period. Any holding in stock – No
5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or;

Managed or co-managed public offering of the securities from the subject company of this research report and / or;

Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report;

ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Term& Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.

DEFINITION OF RATINGS	
Ratings	Expected absolute returns over 12-18 months
BUY	More than 10%
 HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward-looking estimates for the stock but we refrain from assigning valuation and recommendation
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NO STANCE	We do not have any forward looking estimates, valuation or recommendation for the stock

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United States (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alterations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, SEBI Single Reg. No.- NSE, BSE & MSEI – INZ000161633, ARN No. 64610, CDSL-IN-DP-CDSL-693-2013, SEBI-Research Analyst Reg. No. INH 000000297, SEBI Portfolio Manager Reg. No.- INP000000654, Main/Dealing off.- 1st Floor, I-Rise Building, Q Parc, Loma Park, Thane, Ghansoli, Navi Mumbai-400701, Regd. off.- Axis House,8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: AnandShaha, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706